CR20170090A - Derivados de terahidroquinolina como inhibidores del bromodominio - Google Patents

Derivados de terahidroquinolina como inhibidores del bromodominio

Info

Publication number
CR20170090A
CR20170090A CR20170090A CR20170090A CR20170090A CR 20170090 A CR20170090 A CR 20170090A CR 20170090 A CR20170090 A CR 20170090A CR 20170090 A CR20170090 A CR 20170090A CR 20170090 A CR20170090 A CR 20170090A
Authority
CR
Costa Rica
Prior art keywords
terahydroquinoline
bromodominum
inhibitors
derivatives
compounds
Prior art date
Application number
CR20170090A
Other languages
English (en)
Inventor
Stephen John Atkinson
Phillip G Humphreys
Jonathan Thomas Seal
David Jonathan Hirst
Matthew J Lindon
Alexander G Preston
Christopher Roland Wellaway
Original Assignee
Glaxosmithkline Intellectual Property (No 2) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property (No 2) Ltd filed Critical Glaxosmithkline Intellectual Property (No 2) Ltd
Publication of CR20170090A publication Critical patent/CR20170090A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a nuevos compuestos, a composiciones farmacéuticas que contienen tales compuestos y a su uso en terapia
CR20170090A 2014-09-12 2015-09-09 Derivados de terahidroquinolina como inhibidores del bromodominio CR20170090A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462049449P 2014-09-12 2014-09-12
PCT/EP2015/070665 WO2016038120A1 (en) 2014-09-12 2015-09-09 Tetrahydroquinoline derivatives as bromodomain inhibitors

Publications (1)

Publication Number Publication Date
CR20170090A true CR20170090A (es) 2017-05-08

Family

ID=54065889

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170090A CR20170090A (es) 2014-09-12 2015-09-09 Derivados de terahidroquinolina como inhibidores del bromodominio

Country Status (35)

Country Link
US (1) US10059699B2 (es)
EP (1) EP3191476B1 (es)
JP (1) JP6531167B2 (es)
KR (1) KR20170054421A (es)
CN (1) CN106687453B (es)
AR (1) AR101806A1 (es)
AU (1) AU2015314184B2 (es)
BR (1) BR112017004580A2 (es)
CA (1) CA2958159A1 (es)
CL (1) CL2017000587A1 (es)
CO (1) CO2017001601A2 (es)
CR (1) CR20170090A (es)
CY (1) CY1121369T1 (es)
DK (1) DK3191476T3 (es)
DO (1) DOP2017000058A (es)
EA (1) EA031679B9 (es)
ES (1) ES2705623T3 (es)
HR (1) HRP20182064T1 (es)
HU (1) HUE041694T2 (es)
IL (1) IL250397A0 (es)
LT (1) LT3191476T (es)
MA (1) MA40366A (es)
MX (1) MX2017003219A (es)
PE (1) PE20170675A1 (es)
PH (1) PH12017500348B1 (es)
PL (1) PL3191476T3 (es)
PT (1) PT3191476T (es)
RS (1) RS58135B1 (es)
SG (1) SG11201701043UA (es)
SI (1) SI3191476T1 (es)
TR (1) TR201820050T4 (es)
TW (1) TWI686389B (es)
UY (1) UY36292A (es)
WO (1) WO2016038120A1 (es)
ZA (1) ZA201700883B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151727A1 (es) 2013-03-14 2015-12-17 Boehringer Ingelheim Int Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
EP3191487B1 (en) 2014-09-12 2019-08-07 Boehringer Ingelheim International GmbH Spirocyclic inhibitors of cathepsin c
WO2018111805A1 (en) 2016-12-13 2018-06-21 St. Jude Children's Research Hospital Tetrahydroquinoline-based bromodomain inhibitors
AU2019372121A1 (en) 2018-10-30 2021-05-27 Nuvation Bio Inc. Heterocyclic compounds as BET inhibitors
KR102677015B1 (ko) 2019-07-02 2024-06-19 누베이션 바이오 인크. Bet 억제제로서의 헤테로시클릭 화합물
EP4095128A1 (en) 2021-05-25 2022-11-30 Centre national de la recherche scientifique Tetrahydroquinoline (thq) coumpounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2415764A4 (en) * 2009-03-31 2012-08-08 Kowa Co PROPHYLACTIC AND / OR THERAPEUTIC AGENT AGAINST ANEMIA WITH A TETRAHYDROCHINOLINE COMPOUND AS AN ACTIVE SUBSTANCE
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB201106743D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201106750D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201107325D0 (en) 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
NZ710765A (en) * 2013-03-14 2020-05-29 Glaxosmithkline Ip No 2 Ltd 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors

Also Published As

Publication number Publication date
CN106687453A8 (zh) 2017-06-30
JP6531167B2 (ja) 2019-06-12
PH12017500348A1 (en) 2017-07-17
PE20170675A1 (es) 2017-06-13
RS58135B1 (sr) 2019-02-28
TW201625587A (zh) 2016-07-16
CY1121369T1 (el) 2020-05-29
EP3191476A1 (en) 2017-07-19
TR201820050T4 (tr) 2019-01-21
CL2017000587A1 (es) 2017-10-06
AU2015314184B2 (en) 2018-09-13
PL3191476T3 (pl) 2019-04-30
PT3191476T (pt) 2019-01-17
BR112017004580A2 (pt) 2018-01-23
EA031679B1 (ru) 2019-02-28
DOP2017000058A (es) 2017-06-15
MA40366A (fr) 2017-07-19
KR20170054421A (ko) 2017-05-17
SG11201701043UA (en) 2017-03-30
CN106687453B (zh) 2019-07-19
SI3191476T1 (sl) 2019-01-31
ZA201700883B (en) 2021-08-25
US10059699B2 (en) 2018-08-28
EA201790484A1 (ru) 2017-10-31
EP3191476B1 (en) 2018-10-24
ES2705623T3 (es) 2019-03-26
HRP20182064T1 (hr) 2019-02-08
LT3191476T (lt) 2019-01-10
WO2016038120A1 (en) 2016-03-17
HUE041694T2 (hu) 2019-05-28
EA031679B9 (ru) 2019-04-30
AR101806A1 (es) 2017-01-11
DK3191476T3 (en) 2019-01-14
JP2017526718A (ja) 2017-09-14
CO2017001601A2 (es) 2017-07-28
IL250397A0 (en) 2017-03-30
CA2958159A1 (en) 2016-03-17
CN106687453A (zh) 2017-05-17
MX2017003219A (es) 2017-06-19
PH12017500348B1 (en) 2017-07-17
AU2015314184A1 (en) 2017-03-09
TWI686389B (zh) 2020-03-01
UY36292A (es) 2016-04-29
US20170298047A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
DOP2017000298A (es) Reguladores de nrf2
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
GEP20217239B (en) Pharmaceutical composition
PH12016501151A1 (en) Nrf2 regulators
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
BR112016012146A8 (pt) derivados de aminopiridina como inibidores de quinase da família tam
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
CL2015002897A1 (es) Inhibidores de bace1
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112017028549A2 (pt) derivados de pirimidina como inibidores de btk e usos dos mesmos
GEP20217240B (en) Pharmaceutical composition
CR20160448A (es) Nuevos derivados de piridina
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
SG10201900598TA (en) Factor viii formulation